- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05589467
Effects of Potatoes on Blood Pressure in Persons With and Without Type 2 Diabetes Who Follow the DASH Diet for 6 Weeks
What Are the Effects of Potatoes, Utilizing Specific Cooking Methods, on Blood Pressure in Hypertensive Persons With and Without Type II Diabetes Who Follow the DASH Diet for 6 Weeks?
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Subjects will follow the DASH diet for 2 weeks to establish baseline blood pressure and then will be randomized to a 4-week intervention study with assigned dietary patterns (DASH-NP as a control diet, DASH-FP diet with only fried potatoes, or DASH-NFP diet with only non-fried potatoes) in accordance with the protocol given above. Before intervention, each group will receive a cooking demonstrations, samples, and recipes to show the correct preparation method and seasoning ingredient to use according to each treatment group. The control group will receive a cooking demonstration including DASH diet recipes without potatoes. Potatoes will be provided for participants in the potato groups allowing for one serving a day of potatoes prepared according to their treatment group.
The control diet will be the standard DASH diet but with no potatoes. DASH-FP will include 5 servings of fried potatoes each week. DASH-NFP will include 5 servings of non-fried potatoes each week. Participants will be instructed to maintain the broad requirements of the DASH diet on their own. A 7-day menu cycle from the DASH-Sodium study for each dietary pattern at different energy levels will be used as the basis for the recommended diets. There will be weekly contact with the participants in which the DASH diet will be reinforced. The goal of the weekly sessions will be to assist participants in learning how to buy and prepare the appropriate foods according to their dietary pattern, to enhance their motivation to choose to eat those foods, and to overcome obstacles to following the diet.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Shannon Galyean, PhD
- Phone Number: 806-535-2492
- Email: shannon.galyean@ttu.edu
Study Locations
-
-
Texas
-
Lubbock, Texas, United States, 79409
- Texas Tech University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Group 1:
-Well controlled type 2 diabetes as diagnosed by a physician, which is managed by diet and exercise alone or any diabetes medication(s) other than insulin; clinically stable.
Group 2:
-No diagnosis of type 2 diabetes
Group 1 and 2 Exclusion Criteria:
- Use of tobacco
- Self-reported history of chronic diseases other than type 2 diabetes (e.g., cardiovascular, etc.)
- Evidence of severe diabetic complications (such as proliferative retinopathy or diabetic nephropathy)
- Uncontrolled hypertension
- Use of oral steroids, hormone replacement therapy
- Individuals with blood pressure ≥160/100, or HbA1c ≥9%
- Individuals with allergy to potatoes
- Pregnant or lactating
- Individuals on insulin therapy
- Any alcohol or drug dependence
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: DASH Diet and Fried Potatoes
DASH-FP (fried potatoes) group
|
Dash diet with only fried potatoes
|
Experimental: DASH Diet and Non-Fried Potatoes
DASH-NFP (non-fried potatoes) group
|
Dash diet with only non-fried potatoes
|
Experimental: DASh Diet and No Potatoes
DASH-NP (no potatoes) group
|
Dash diet with no potatoes
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Systolic and Diastolic blood pressure in mmHg
Time Frame: at baseline
|
After the subject has rested for five minutes in a sitting position, blood pressure measurements will be taken, using an Omron IntelliSense® Blood Pressure Monitor using an arm cuff suitable for the body size.
Three readings will be taken at five-minute intervals and the average of the three measurements used.
|
at baseline
|
Systolic and Diastolic blood pressure in mmHg
Time Frame: 2 weeks
|
After the subject has rested for five minutes in a sitting position, blood pressure measurements will be taken, using an Omron IntelliSense® Blood Pressure Monitor using an arm cuff suitable for the body size.
Three readings will be taken at five-minute intervals and the average of the three measurements used.
|
2 weeks
|
Systolic and Diastolic blood pressure in mmHg
Time Frame: 6 weeks
|
After the subject has rested for five minutes in a sitting position, blood pressure measurements will be taken, using an Omron IntelliSense® Blood Pressure Monitor using an arm cuff suitable for the body size.
Three readings will be taken at five-minute intervals and the average of the three measurements used.
|
6 weeks
|
Body mass index in kg/m^2
Time Frame: at baseline
|
weight in kg and height in meters will be used to calculate BMI
|
at baseline
|
Waist circumference in inches
Time Frame: at baseline
|
A certified non-stretch tape measure will be used to measure waist circumference (WC) at the natural waist (mid-way between the 10th rib and the ileac crest) as recommended by the World Health Organization and hip circumference over the widest point over the buttocks to the nearest centimeter.
|
at baseline
|
Waist circumference in inches
Time Frame: 2 weeks
|
A certified non-stretch tape measure will be used to measure waist circumference (WC) at the natural waist (mid-way between the 10th rib and the ileac crest) as recommended by the World Health Organization and hip circumference over the widest point over the buttocks to the nearest centimeter.
|
2 weeks
|
Waist circumference in inches
Time Frame: 6 weeks
|
A certified non-stretch tape measure will be used to measure waist circumference (WC) at the natural waist (mid-way between the 10th rib and the ileac crest) as recommended by the World Health Organization and hip circumference over the widest point over the buttocks to the nearest centimeter.
|
6 weeks
|
body composition in body fat percentage
Time Frame: at baseline
|
Body composition (fat and lean body mass) will be measured by bioelectric impedance using a Tanita scale (model SC-331S Tanita, Tokyo, Japan).
|
at baseline
|
body composition in body fat percentage
Time Frame: 2 weeks
|
Body composition (fat and lean body mass) will be measured by bioelectric impedance using a Tanita scale (model SC-331S Tanita, Tokyo, Japan).
|
2 weeks
|
body composition in body fat percentage
Time Frame: 6 weeks
|
Body composition (fat and lean body mass) will be measured by bioelectric impedance using a Tanita scale (model SC-331S Tanita, Tokyo, Japan).
|
6 weeks
|
weight in lbs
Time Frame: at baseline
|
Weight will be measure to the nearest 0.1lb
|
at baseline
|
weight in lbs
Time Frame: 2 weeks
|
Weight will be measure to the nearest 0.1 lb
|
2 weeks
|
weight in lbs
Time Frame: 6 weeks
|
Weight will be measure to the nearest 0.1 lb
|
6 weeks
|
height in centimeters
Time Frame: at baseline
|
Height will be measured to the nearest 0.1 cm using a stadiometer.
|
at baseline
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
General Publications
- Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, Obarzanek E, Conlin PR, Miller ER 3rd, Simons-Morton DG, Karanja N, Lin PH; DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001 Jan 4;344(1):3-10. doi: 10.1056/NEJM200101043440101.
- Svetkey LP, Sacks FM, Obarzanek E, Vollmer WM, Appel LJ, Lin PH, Karanja NM, Harsha DW, Bray GA, Aickin M, Proschan MA, Windhauser MM, Swain JF, McCarron PB, Rhodes DG, Laws RL. The DASH Diet, Sodium Intake and Blood Pressure Trial (DASH-sodium): rationale and design. DASH-Sodium Collaborative Research Group. J Am Diet Assoc. 1999 Aug;99(8 Suppl):S96-104. doi: 10.1016/s0002-8223(99)00423-x.
- Obarzanek E, Sacks FM, Vollmer WM, Bray GA, Miller ER 3rd, Lin PH, Karanja NM, Most-Windhauser MM, Moore TJ, Swain JF, Bales CW, Proschan MA; DASH Research Group. Effects on blood lipids of a blood pressure-lowering diet: the Dietary Approaches to Stop Hypertension (DASH) Trial. Am J Clin Nutr. 2001 Jul;74(1):80-9. doi: 10.1093/ajcn/74.1.80.
- Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K, Shaw JE, Bright D, Williams R; IDF Diabetes Atlas Committee. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019 Nov;157:107843. doi: 10.1016/j.diabres.2019.107843. Epub 2019 Sep 10.
- Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, Bray GA, Vogt TM, Cutler JA, Windhauser MM, Lin PH, Karanja N. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med. 1997 Apr 17;336(16):1117-24. doi: 10.1056/NEJM199704173361601.
- International Diabetes Federation. IDF Diabetes Atlas, 9th Edn. Brussels, Belgium: International Diabetes Federation, 2019. http://www.diabetesatlas.org
- Gurushankar Govindarajan, James R Sowers, Craig S Stump (2016) Volume 2, Issue 1 Hypertension and Diabetes Mellitus https://doi.org/10.15420/ecr.2006.1.21
- Aljuraiban GS, Pertiwi K, Stamler J, Chan Q, Geleijnse JM, Van Horn L, Daviglus ML, Elliott P, Oude Griep LM; INTERMAP Research Group. Potato consumption, by preparation method and meal quality, with blood pressure and body mass index: The INTERMAP study. Clin Nutr. 2020 Oct;39(10):3042-3048. doi: 10.1016/j.clnu.2020.01.007. Epub 2020 Jan 22.
- Azadbakht L, Fard NR, Karimi M, Baghaei MH, Surkan PJ, Rahimi M, Esmaillzadeh A, Willett WC. Effects of the Dietary Approaches to Stop Hypertension (DASH) eating plan on cardiovascular risks among type 2 diabetic patients: a randomized crossover clinical trial. Diabetes Care. 2011 Jan;34(1):55-7. doi: 10.2337/dc10-0676. Epub 2010 Sep 15.
- Azadbakht L, Mirmiran P, Esmaillzadeh A, Azizi T, Azizi F. Beneficial effects of a Dietary Approaches to Stop Hypertension eating plan on features of the metabolic syndrome. Diabetes Care. 2005 Dec;28(12):2823-31. doi: 10.2337/diacare.28.12.2823.
- Beals, K. A. (2019). Potatoes, Nutrition and Health. American Journal of Potato Research, 96(2), 102-110. doi:10.1007/s12230-018-09705-4
- Berraho M, El Achhab Y, Benslimane A, El Rhazi K, Chikri M, Nejjari C. Hypertension and type 2 diabetes: a cross-sectional study in Morocco (EPIDIAM Study). Pan Afr Med J. 2012;11:52. Epub 2012 Mar 20.
- Challa, H. J., Ameer, M. A., & Uppaluri, K. R. (2020). DASH Diet (Dietary Approaches to Stop Hypertension). In StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2020, StatPearls Publishing LLC. 35 45 44
- Challa, H. J., Tadi, P., & Uppaluri, K. R. (2019). DASH Diet (Dietary Approaches to Stop Hypertension): StatPearls Publishing, Treasure Island (FL).
- Chen G, McAlister FA, Walker RL, Hemmelgarn BR, Campbell NR. Cardiovascular outcomes in framingham participants with diabetes: the importance of blood pressure. Hypertension. 2011 May;57(5):891-7. doi: 10.1161/HYPERTENSIONAHA.110.162446. Epub 2011 Mar 14.
- Cheung BM, Li C. Diabetes and hypertension: is there a common metabolic pathway? Curr Atheroscler Rep. 2012 Apr;14(2):160-6. doi: 10.1007/s11883-012-0227-2.
- Cook NR, Cutler JA, Obarzanek E, Buring JE, Rexrode KM, Kumanyika SK, Appel LJ, Whelton PK. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ. 2007 Apr 28;334(7599):885-8. doi: 10.1136/bmj.39147.604896.55. Epub 2007 Apr 20.
- de Paula TP, Steemburgo T, de Almeida JC, Dall'Alba V, Gross JL, de Azevedo MJ. The role of Dietary Approaches to Stop Hypertension (DASH) diet food groups in blood pressure in type 2 diabetes. Br J Nutr. 2012 Jul 14;108(1):155-62. doi: 10.1017/S0007114511005381. Epub 2011 Dec 6.
- Drewnowski A. The Nutrient Rich Foods Index helps to identify healthy, affordable foods. Am J Clin Nutr. 2010 Apr;91(4):1095S-1101S. doi: 10.3945/ajcn.2010.28450D. Epub 2010 Feb 24.
- Ferrannini E, Cushman WC. Diabetes and hypertension: the bad companions. Lancet. 2012 Aug 11;380(9841):601-10. doi: 10.1016/S0140-6736(12)60987-8.
- Halton TL, Willett WC, Liu S, Manson JE, Stampfer MJ, Hu FB. Potato and french fry consumption and risk of type 2 diabetes in women. Am J Clin Nutr. 2006 Feb;83(2):284-90. doi: 10.1093/ajcn/83.2.284.
- Hashemi R, Rahimlou M, Baghdadian S, Manafi M. Investigating the effect of DASH diet on blood pressure of patients with type 2 diabetes and prehypertension: Randomized clinical trial. Diabetes Metab Syndr. 2019 Jan-Feb;13(1):1-4. doi: 10.1016/j.dsx.2018.06.014. Epub 2018 Jun 21.
- He FJ, MacGregor GA. Effect of modest salt reduction on blood pressure: a meta-analysis of randomized trials. Implications for public health. J Hum Hypertens. 2002 Nov;16(11):761-70. doi: 10.1038/sj.jhh.1001459.
- Heller, M. (2011). The DASH Diet Action Plan: Proven to Lower Blood Pressure and Cholesterol Without Medication: Grand Central Publishing.
- Houston MC, Harper KJ. Potassium, magnesium, and calcium: their role in both the cause and treatment of hypertension. J Clin Hypertens (Greenwich). 2008 Jul;10(7 Suppl 2):3-11. doi: 10.1111/j.1751-7176.2008.08575.x.
- Hu G, Jousilahti P, Tuomilehto J. Joint effects of history of hypertension at baseline and type 2 diabetes at baseline and during follow-up on the risk of coronary heart disease. Eur Heart J. 2007 Dec;28(24):3059-66. doi: 10.1093/eurheartj/ehm501. Epub 2007 Nov 2.
- Huang M, Zhuang P, Jiao J, Wang J, Chen X, Zhang Y. Potato consumption is prospectively associated with risk of hypertension: An 11.3-year longitudinal cohort study. Clin Nutr. 2019 Aug;38(4):1936-1944. doi: 10.1016/j.clnu.2018.06.973. Epub 2018 Jul 2.
- Johnston EA, Petersen KS, Kris-Etherton PM. Daily intake of non-fried potato does not affect markers of glycaemia and is associated with better diet quality compared with refined grains: a randomised, crossover study in healthy adults. Br J Nutr. 2020 May 14;123(9):1032-1042. doi: 10.1017/S0007114520000252. Epub 2020 Jan 22.
- Kolasa, K. M. (1993). The potato and human nutrition. American Potato Journal, 70(5), 375-384. doi:10.1007/BF02849118
- Liese AD, Nichols M, Sun X, D'Agostino RB Jr, Haffner SM. Adherence to the DASH Diet is inversely associated with incidence of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes Care. 2009 Aug;32(8):1434-6. doi: 10.2337/dc09-0228. Epub 2009 Jun 1.
- Malloy-McFall J, Barkley JE, Gordon KL, Burzminski N, Glickman EL. Effect of the DASH Diet on Pre- and Stage 1 Hypertensive Individuals in a Free-Living Environment. Nutr Metab Insights. 2010 Mar 31;3:15-23. doi: 10.4137/NMI.S3871. eCollection 2010.
- Mubarak FM, Froelicher ES, Jaddou HY, Ajlouni KM. Hypertension among 1000 patients with type 2 diabetes attending a national diabetes center in Jordan. Ann Saudi Med. 2008 Sep-Oct;28(5):346-51. doi: 10.5144/0256-4947.2008.346.
- Muraki I, Rimm EB, Willett WC, Manson JE, Hu FB, Sun Q. Potato Consumption and Risk of Type 2 Diabetes: Results From Three Prospective Cohort Studies. Diabetes Care. 2016 Mar;39(3):376-84. doi: 10.2337/dc15-0547. Epub 2015 Dec 17.
- Nguyen H, Odelola OA, Rangaswami J, Amanullah A. A review of nutritional factors in hypertension management. Int J Hypertens. 2013;2013:698940. doi: 10.1155/2013/698940. Epub 2013 Apr 10.
- Hu EA, Martinez-Gonzalez MA, Salas-Salvado J, Corella D, Ros E, Fito M, Garcia-Rodriguez A, Estruch R, Aros F, Fiol M, Lapetra J, Serra-Majem L, Pinto X, Ruiz-Canela M, Razquin C, Bullo M, Sorli JV, Schroder H, Rebholz CM, Toledo E; PREDIMED Study and SUN Project Investigators. Potato Consumption Does Not Increase Blood Pressure or Incident Hypertension in 2 Cohorts of Spanish Adults. J Nutr. 2017 Dec;147(12):2272-2281. doi: 10.3945/jn.117.252254. Epub 2017 Oct 18.
- Venugopal, K., & Mohammed, M. (2014). Prevalence of hypertension in type-2 diabetes mellitus. CHRISMED Journal of Health and Research, 1(4), 223-227. doi:10.4103/2348-3334.142981 38 45 44
- Vinson JA, Demkosky CA, Navarre DA, Smyda MA. High-antioxidant potatoes: acute in vivo antioxidant source and hypotensive agent in humans after supplementation to hypertensive subjects. J Agric Food Chem. 2012 Jul 11;60(27):6749-54. doi: 10.1021/jf2045262. Epub 2012 Feb 6.
- Whelton SP, Hyre AD, Pedersen B, Yi Y, Whelton PK, He J. Effect of dietary fiber intake on blood pressure: a meta-analysis of randomized, controlled clinical trials. J Hypertens. 2005 Mar;23(3):475-81. doi: 10.1097/01.hjh.0000160199.51158.cf.
- Zaheer K, Akhtar MH. Potato Production, Usage, and Nutrition--A Review. Crit Rev Food Sci Nutr. 2016;56(5):711-21. doi: 10.1080/10408398.2012.724479.
- Zhang Y, You D, Lu N, Duan D, Feng X, Astell-Burt T, Zhu P, Han L, Duan S, Zou Z. Potatoes Consumption and Risk of Type 2 Diabetes: A Meta-analysis. Iran J Public Health. 2018 Nov;47(11):1627-1635.
- Zou P, Dennis CL, Lee R, Parry M. Dietary Approach to Stop Hypertension with Sodium Reduction for Chinese Canadians (DASHNa-CC): A Pilot Randomized Controlled Trial. J Nutr Health Aging. 2017;21(10):1225-1232. doi: 10.1007/s12603-016-0861-4.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB2019-880
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes
-
Antonio Di MauroCompletedType-2 DiabetesItaly
-
DiaMedica Therapeutics IncCompletedDiabetes Type 2Netherlands
-
RenJi HospitalUnknownType 2 Diabetes.China
-
University of Erlangen-Nürnberg Medical SchoolCompletedType 2-diabetesGermany
-
Chengdu Brilliant Pharmaceutical Co., Ltd.Not yet recruitingType 2 Diabetes Mellitus
-
Nanjing First Hospital, Nanjing Medical UniversityRecruitingType 2 Diabetes MellitusChina
-
Xiangya Hospital of Central South UniversityRecruitingType 2 Diabetes MellitusChina
-
University of Alabama at BirminghamCompletedType 2 Diabetes MellitusUnited States
-
Imperial College LondonAstraZeneca; Huma; North West London Collaboration of CCGs (NWL CCGs); Imperial...CompletedType 2 Diabetes MellitusUnited Kingdom
-
Universiti Sains MalaysiaCompleted
Clinical Trials on DASH-FP
-
Johns Hopkins UniversityNational Institute on Minority Health and Health Disparities (NIMHD)Completed
-
Case Western Reserve UniversityCompleted
-
FHI 360Ministry of Health, UgandaCompletedCommunity-based Delivery of Integrated Family Planning/HIV Testing and Counseling Services in UgandaHIV Testing and CounselingUganda
-
Johns Hopkins UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedHigh Blood PressureUnited States
-
Immune Targeting Systems LtdCompleted
-
Duke UniversityCompletedCardiovascular Diseases | Hypertension | Diet Modification | Women's Health | Digital HealthUnited States
-
National Health Research Institutes, TaiwanTaipei Veterans General Hospital, TaiwanUnknown
-
Foresee Pharmaceuticals Co., Ltd.Completed
-
University of MichiganTerminatedDiastolic Heart Failure | Hypertensive Heart DiseaseUnited States
-
Assiut UniversityNot yet recruitingDyslipidemia Associated With Type II Diabetes Mellitus